Real-world Clinical And Demographic Characteristics Associated With Progression To Type 2 Diabetes In Patients With Prediabetes
Moderator
Tyler James Dunn, BS, MS, PhD
Speakers
Justin Chen, BSc, MSc; Victoria Divino; Riddhi Doshi; Josh Noone; Michael Radin; Dajun Tian; Lin Xie, MA, MS; Carolina Solis-Herrera, MD
OBJECTIVES: This study aimed to compare clinical and demographic characteristics of US patients with prediabetes one year before progression to type 2 diabetes (T2D) with those who did not progress.
METHODS: IQVIA’s PharMetrics® Plus and linked Ambulatory Electronic Medical Records databases were utilized to identify T2D progressors (cases) or non-progressors (controls) between January 2017 and January 2024. All patients included demonstrated prediabetes within a 12-month pre-index period, during which demographic, clinical, and healthcare resource usage were compared between the groups.
RESULTS: Compared to controls (n = 58,751), cases (n = 39,281) were younger (mean [SD]; 55.8 [10.9] vs. 56.8 [11.8] years) and more likely to be female (53.1% vs. 50.8%) and with self-insured healthcare coverage (28.6% vs. 23.1%). Cases had greater prevalence of obesity (47.1% vs. 31.9%), cardiovascular disease (72.9% vs. 60.4%) and hypertension (67.7% vs. 54.0%). Any-, oral-, and injectable-anti-diabetic medication (ADM) was more common in cases (36.0%, 33.7% and 4.6%, respectively) than controls (5.6%, 4.8% and 1.2%, respectively). Metformin was the most common ADM used by cases (32.1%) and controls (4.6%), and glucagon-like peptide (GLP)-1 receptor agonists were uncommon but used more among cases (4.3%) than controls (1.1%) for T2D. Outpatient medical service use and outpatient drug claims were more frequent among cases (median [IQR]: 34 [20-58] vs. 27 [16-46] services and 23 [11-41] vs. 16 [7-29] claims, respectively). Accordingly, median [IQR] total healthcare costs were higher for cases ($5,096 [$2,026-$13,513] vs. $3,477 [$1,462-$9,002]), driven by outpatient medical services ($2,861 [$1,205-$6,923] vs. $2,171 [$973-$5,097]) and drug costs ($663 [$219-$2,483] vs. $421 [$132-$1,417]). All differences mentioned were significant at p<0.001.
CONCLUSIONS: Limited attention has been given to exploring real-world evidence regarding patient factors preceding progression from prediabetes to T2D. The findings may inform and aid treatment strategies in at-risk patients, enabling proactive intervention to mitigate disease progression.
METHODS: IQVIA’s PharMetrics® Plus and linked Ambulatory Electronic Medical Records databases were utilized to identify T2D progressors (cases) or non-progressors (controls) between January 2017 and January 2024. All patients included demonstrated prediabetes within a 12-month pre-index period, during which demographic, clinical, and healthcare resource usage were compared between the groups.
RESULTS: Compared to controls (n = 58,751), cases (n = 39,281) were younger (mean [SD]; 55.8 [10.9] vs. 56.8 [11.8] years) and more likely to be female (53.1% vs. 50.8%) and with self-insured healthcare coverage (28.6% vs. 23.1%). Cases had greater prevalence of obesity (47.1% vs. 31.9%), cardiovascular disease (72.9% vs. 60.4%) and hypertension (67.7% vs. 54.0%). Any-, oral-, and injectable-anti-diabetic medication (ADM) was more common in cases (36.0%, 33.7% and 4.6%, respectively) than controls (5.6%, 4.8% and 1.2%, respectively). Metformin was the most common ADM used by cases (32.1%) and controls (4.6%), and glucagon-like peptide (GLP)-1 receptor agonists were uncommon but used more among cases (4.3%) than controls (1.1%) for T2D. Outpatient medical service use and outpatient drug claims were more frequent among cases (median [IQR]: 34 [20-58] vs. 27 [16-46] services and 23 [11-41] vs. 16 [7-29] claims, respectively). Accordingly, median [IQR] total healthcare costs were higher for cases ($5,096 [$2,026-$13,513] vs. $3,477 [$1,462-$9,002]), driven by outpatient medical services ($2,861 [$1,205-$6,923] vs. $2,171 [$973-$5,097]) and drug costs ($663 [$219-$2,483] vs. $421 [$132-$1,417]). All differences mentioned were significant at p<0.001.
CONCLUSIONS: Limited attention has been given to exploring real-world evidence regarding patient factors preceding progression from prediabetes to T2D. The findings may inform and aid treatment strategies in at-risk patients, enabling proactive intervention to mitigate disease progression.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
CO41
Topic
Clinical Outcomes
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity)